|
WO2020227062A1
|
|
Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins
|
|
WO2020214928A1
|
|
Bioassay for t-cell co-stimulatory proteins containing fc domains
|
|
WO2020172482A2
|
|
Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
|
|
CA3114955A1
|
|
Combination therapy for cancer
|
|
CA3112215A1
|
|
Anti-fgfr2 antibody formulations
|
|
WO2020047087A1
|
|
Cd80 extracellular domain fc fusion protein dosing regimens
|
|
WO2020014327A2
|
|
Antibodies binding to vista at acidic ph
|
|
AR115728A1
|
|
IL-T4 UNION ANTIBODIES
|
|
AR115729A1
|
|
VISIBLE BINDING ANTIBODIES IN ACID pH
|
|
WO2020014132A2
|
|
Antibodies binding to ilt4
|
|
WO2019226897A2
|
|
Enhanced cytometry for tissue characterization and screening
|
|
CN111971304A
|
|
Antibodies binding to VISTA at acidic pH
|
|
AU2019228600A1
|
|
B7-H4 antibodies and methods of use thereof
|
|
JP2019089840A
|
|
Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
KR20200123169A
|
|
B7-H4 antibody dosing regimen
|
|
WO2019165077A1
|
|
B7-h4 antibody formulations
|
|
CN111479586A
|
|
Combination therapy combining anti-CSF 1R and anti-PD-1 antibodies for pancreatic cancer
|
|
CN111094352A
|
|
B7-H4 antibodies and methods of use thereof
|
|
KR20200006538A
|
|
Anti-FGFR2 Antibody in Combination with Chemotherapy in Cancer Treatment
|
|
EP3628070A1
|
|
Methods of treatment with cd80 extracellular domain polypeptides
|
